<DOC>
	<DOC>NCT00907322</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Dimebon following single ascending doses. A formal single ascending dose study of this nature has not been performed to date in the Dimebon development program.</brief_summary>
	<brief_title>A Phase 1 Trial To Assess The Safety And Pharmacokinetics Of Single, Ascending, Oral Doses Of Dimebon In Healthy Adults</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. Subjects who display the CYP2D6 extensive, intermediate, ultrarapid, or poor metabolizer statuses. A known history of hypersensitivity or previous intolerance to Dimebon or other antihistamines. Subjects with any previous history of seizures, convulsions, epilepsy, or significant head injury. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>oral, single ascending doses; CYP2D6 metabolizer status; healthy subjects; safety, tolerability, pharmacokinetics</keyword>
</DOC>